If the gut works; use it! Malabsorptionmarkers in patients with a haematological-oncological disease after stem cell transplantation, with treatment-related mucositis or graft-versus-host disease of the digestive tract

If the gut works; use it! Malabsorptionmarkers in patients with a haematological-oncological disease after stem cell transplantation, with treatment-related mucositis or graft-versus-host disease of the digestive tract - MAST - MAlabsorption study before and after Stemcel Transplantation

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON55088

Enrollment

Registered

2021-12-22

Start date

2022-06-02

Completion date

Unknown

Last updated

2025-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematologische aandoeningen waarvoor behandeld wordt met een autologe of allogene stamceltransplantatie bloodcancer hematology

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Clinical admitted adult patients with hematological malignancies - Suffer from chemotherapy- or GVHD-induced-mucositis with diarrhea

Exclusion criteria

Exclusion criteria: - Unable to speak, read or write Dutch or English language - Pregnant or lactating women - Weight

Design outcomes

Primary

Measure	Time frame
Primary endpoint of this study is the incidence of malabsorption and the level of severity of malabsorption in patients with hematological malignancies with chemotherapy- or GVHD-induced-mucositis by standard fecal analysis in combination with dietary (oral/enteral) intake of energy and macronutrients (as percentage intestinal absorption capacity).	—

Secondary

Measure	Time frame
Secondary endpoints are the accuracy and applicability of fecal volume and citrulline (generation) test (CGT) as markers for malabsorption compared standard procedures (fecal analyses in combination with dietary intake) in these patients.	—

Countries

Netherlands

Outcome results